Oncodesign Precision Medicine Société anonyme Reports Full Year 2024 Earnings

Oncodesign Precision Medicine Société anonyme (EPA:ALOPM) Full Year 2024 Results

Key Financial Results

• Net loss: €7.20m (loss narrowed by 11% from FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Oncodesign Precision Medicine Société anonyme Earnings Insights

Looking ahead, revenue is expected to decline by 12% p.a. on average during the next 3 years, while revenues in the Biotechs industry in France are expected to grow by 25%.

Performance of the French Biotechs industry.

The company's shares are down 5.1% from a week ago.

Risk Analysis

You should learn about the 3 warning signs we've spotted with Oncodesign Precision Medicine Société anonyme (including 2 which are significant) .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.